TY - JOUR
T1 - Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer
T2 - Case Report and Literature Review
AU - Lee, Matthew
AU - Patel, Dhruv
AU - Jofre, Sebastian
AU - Fidvi, Shabnam
AU - Suhrland, Mark
AU - Cohen, Perry
AU - Cheng, Haiying
N1 - Funding Information:
No funding support was provided, would like to acknowledge the support of Dr Sebastian Jofre, Dr Perry Cohen and Dr Mark Suhrland from Pathology Department in providing histopathological images and Dr Shabnam Fidvi from Radiology Department in assisting in the radiological images.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2022/5
Y1 - 2022/5
N2 - • New metastatic sites in non-small cell lung cancer (NSCLC) patients have been shown to have the potential to transform into another histologic subtype that is different from the original histology of the patient while on treatment. • These histological transformations can indicate potential resistance mechanisms to current or prior treatments and can prompt a change in management in patients. • However, little is known about histologic transformations in NSCLC patients and what are the next steps in management. • New reports have shown that epidermal growth factor receptor tyrosine kinase inhibitors such as osimertinib can also lead to these histologic transformations in NSCLC cases and rarely to either large cell neuroendocrine carcinomas or small cell carcinoma. • This case highlights the important implications for these patients since the treatment plans are different and changes in prognosis and for clinicians to be aware of these possibilities and consider repeat biopsies and genomic testing to optimize treatment.
AB - • New metastatic sites in non-small cell lung cancer (NSCLC) patients have been shown to have the potential to transform into another histologic subtype that is different from the original histology of the patient while on treatment. • These histological transformations can indicate potential resistance mechanisms to current or prior treatments and can prompt a change in management in patients. • However, little is known about histologic transformations in NSCLC patients and what are the next steps in management. • New reports have shown that epidermal growth factor receptor tyrosine kinase inhibitors such as osimertinib can also lead to these histologic transformations in NSCLC cases and rarely to either large cell neuroendocrine carcinomas or small cell carcinoma. • This case highlights the important implications for these patients since the treatment plans are different and changes in prognosis and for clinicians to be aware of these possibilities and consider repeat biopsies and genomic testing to optimize treatment.
KW - EGFR mutations
KW - Histologic transformation
KW - Resistance mechanisms
UR - http://www.scopus.com/inward/record.url?scp=85114997096&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114997096&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2021.08.002
DO - 10.1016/j.cllc.2021.08.002
M3 - Article
C2 - 34535400
AN - SCOPUS:85114997096
SN - 1525-7304
VL - 23
SP - e276-e282
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 3
ER -
